共 119 条
[1]
Kahn SE(2006)Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427-2443
[2]
Haffner SM(2009)Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 193-203
[3]
Heise MA(1995)Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group Diabetes 44 1249-1258
[4]
Nathan DM(2008)Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 51 1145-1149
[5]
Buse JB(2009)Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 650-657
[6]
Davidson MB(2009)Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 520-526
[7]
Prospective UK(2009)Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 85 513-519
[8]
Meng W(2011)Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 13 928-938
[9]
Ellsworth BA(2012)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 1364-1379
[10]
Nirschl AA(2008)Improving efficiency of inferences in randomized clinical trials using auxiliary covariates Biometrics 64 707-715